Finnish contract research organisation (CRO) specialising in preclinical brain MRI, molecular neuroscience, and CNS drug development services.
This is a specialist contract research organisation (CRO) based in Kuopio, Finland, operating under the Charles River Laboratories global network and formerly known as Cerebricon — a name still reflected in their website. Their core capability is preclinical brain imaging, particularly advanced MRI methods applied to characterise microstructural changes in brain tissue associated with disease or damage. In EU projects, they serve as a specialist technical partner, contributing validated imaging infrastructure and neuroscience expertise that pharmaceutical and biotech partners typically cannot build in-house. Their work bridges preclinical research tools with the drug development pipeline, covering brain pathology characterisation, neurodevelopmental disorder models, and the regulatory and clinical translation knowledge that moves discoveries toward patient applications.
MICROBRADAM was explicitly focused on advanced MR methods for characterising microstructural brain damage, and MINDED extends this imaging and neuroscience infrastructure into precision therapies for neurodevelopmental disorders.
MINDED lists molecular neuroscience as a core keyword, indicating contributions at the cellular and molecular level alongside imaging work.
MINDED (2018–2024) centres on multiscale precision therapies for neurodevelopmental disorders, positioning the organisation within a therapeutic development context.
MINDED keywords explicitly include clinical integration and regulatory science, suggesting growing involvement in the late-stage translation pathway from research to clinical use.
Nanomedicine appears as a keyword in MINDED, indicating exposure to nanoparticle-based therapeutic delivery approaches for brain and CNS conditions.
In the earlier period (MICROBRADAM, 2015–2019), their H2020 involvement was narrowly focused on advanced MRI methodology — precision tools for measuring brain damage at the microstructural level, a technically deep but scope-limited contribution. By the later project (MINDED, 2018–2024), the keyword profile broadened dramatically to include nanomedicine, cognitive robotics, entrepreneurship, and regulatory science alongside molecular neuroscience, suggesting the organisation stepped into a larger, more interdisciplinary consortium with responsibilities extending beyond imaging alone. The overall trajectory is from specialist imaging provider toward a broader translational neuroscience role that touches therapeutics, regulatory pathways, and clinical readiness.
They are moving from a pure preclinical imaging service role toward integration into full therapeutic development consortia, suggesting future collaborations will likely involve regulatory and clinical translation contributions alongside their established imaging capabilities.
They have never led an H2020 project — in both cases they joined as participant or third-party partner, consistent with the service-provider model typical of contract research organisations. Despite only two projects, they participated in consortia generating 21 unique partners across 12 countries, indicating they are drawn into large international networks rather than small bilateral collaborations. For a potential partner, this means they bring well-defined specialist capability to structured consortia and are experienced at operating within multi-institution teams without needing to manage coordination overhead.
With 21 unique partners and 12 countries across just two projects, their network density is high relative to their project count, a direct consequence of involvement in large MSCA-RISE and MSCA-COFUND schemes that are designed to create wide international mobility networks. Their reach is pan-European with no visible geographic concentration beyond their Finnish base.
As the Finnish operational unit of Charles River Laboratories — one of the world's largest preclinical CRO groups — this organisation offers something rare in academic-heavy EU consortia: professional-grade preclinical infrastructure backed by global quality standards, GLP compliance experience, and the regulatory credibility that a commercial CRO carries. Their Kuopio location also ties them into the University of Eastern Finland's strong neuroscience ecosystem, providing a hybrid academic-commercial positioning. For consortium builders in the CNS space, they fill the gap between university research output and industry-ready preclinical validation.
